PF-06649751 middle dose 1 (3 mg QD)

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

PF-06649751 middle dose 1 (3 mg QD)
Treatment and conditionWhere it standsTrials
PF-06649751 middle dose 1 (3 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1